DESIGN Observational epidemiological study AIMS - To determine: 1. The proportion of immunosuppressed people who have detectable SARS-CoV-2 antibodies following a primary vaccine course (3 doses), and the demographic, disease, and treatment characteristics that influence antibody status. 2. If the detection of antibodies inversely correlates with subsequent risk of severe acute respiratory syndrome coronavirus-2 infection and/or severity of disease in immunosuppressed people.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
The Proportion of Participants With and Without Antibodies to SARS-CoV-2
Timeframe: 21 - 90 days post 3rd vaccine
The Proportion of Participants With and Without Antibodies to SARS-CoV-2
Timeframe: 21 - 90 days post 4th vaccine
The Incidence of Participants Having at Least One RT-qPCR Proven Infection in the 6-month Follow-up Period After 3rd or 4th Vaccine
Timeframe: 6-month follow-up period from registration. Reporting of this is delayed following difficulties with collection of data from national bodies.
The Incidence of Participants Hospitalised Due to COVID-19 and Deaths Due to COVID-19
Timeframe: 6-month follow-up period from registration. Reporting of this is delayed following difficulties with collection of data from national bodies.
Rates of Those With and Without Antibodies to SARS-CoV-2 After 3rd or 4th Vaccine
Timeframe: Antibodies at 21 - 90 days after 3rd or 4th vaccine